•
Jun 30, 2024

ClearPoint Neuro Q2 2024 Earnings Report

Reported record quarterly revenue and achieved double-digit growth across all four pillars.

Key Takeaways

ClearPoint Neuro reported a strong second quarter with record revenue of $7.9 million, a 32% year-over-year increase. Product revenue more than doubled, and the company saw significant growth in Biologics and Drug Delivery revenue and Neurosurgery Navigation revenue. The company also raised its full-year revenue guidance to between $30.0 and $33.0 million.

Reported quarterly revenue of $7.9 million, a 32% year-over-year increase.

Product revenue across all segments more than doubled, growing 112% to $4.9 million.

Increased Biologics and Drug Delivery revenue to $4.3 million, a 28% year-over-year increase.

Operational cash burn reduced to $2.7 million, a 47% year-over-year decrease.

Total Revenue
$7.86M
Previous year: $5.95M
+32.1%
EPS
-$0.16
Previous year: -$0.29
-44.8%
Gross Margin
63%
Gross Profit
$4.99M
Previous year: $3.13M
+59.6%
Cash and Equivalents
$32.8M
Previous year: $26.5M
+23.9%
Free Cash Flow
-$2.67M
Previous year: -$5.4M
-50.6%
Total Assets
$52.6M
Previous year: $47.6M
+10.4%

ClearPoint Neuro

ClearPoint Neuro

ClearPoint Neuro Revenue by Segment

Forward Guidance

The Company is raising its full year 2024 revenue outlook to between $30.0 and $33.0 million.

Positive Outlook

  • Expand our biologics and drug delivery services and customers
  • Add long-term strategic agreements with pharmaceutical partners
  • Assist our biotech partners as they continue first-in-human study initiations
  • Continue our expansion into the operating room with SmartFrame OR
  • Expand our installed base of the PRISM Laser Therapy System under full market release